PDCD1 and neoplasm: While anti-PD-1 treatment alone demonstrated minimal if any activity in this relatively anti-PD1 resistant model (Fig. 6a), enhanced anti-tumor effects were seen in both injected and uninjected tumors with Virus 16 in combination with anti-PD1 antibody therapy as compared to either therapy alone (Fig. 6b-d).